Pledpharma Q2: Completion of POLAR Program on Track
Redeye believes the key takeaway from the Q2 report is that the data collection from the prematurely stopped POLAR program is on track. Thus, a readout looks likely later this year which could constitute a “closure” of the PledOx debacle - with potential upside. Our base case, resting solely on the Aladote project, is unchanged.